It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Microglia nodules (HLA-DR+ cell clusters) are associated with brain pathology. In this post-mortem study, we investigated whether they represent the first stage of multiple sclerosis (MS) lesion formation. We show that microglia nodules are associated with more severe MS pathology. Compared to microglia nodules in stroke, those in MS show enhanced expression of genes previously found upregulated in MS lesions. Furthermore, genes associated with lipid metabolism, presence of T and B cells, production of immunoglobulins and cytokines, activation of the complement cascade, and metabolic stress are upregulated in microglia nodules in MS. Compared to stroke, they more frequently phagocytose oxidized phospholipids and possess a more tubular mitochondrial network. Strikingly, in MS, some microglia nodules encapsulate partially demyelinated axons. Taken together, we propose that activation of microglia nodules in MS by cytokines and immunoglobulins, together with phagocytosis of oxidized phospholipids, may lead to a microglia phenotype prone to MS lesion formation.
Microglia nodules are associated with brain pathology. Here, the authors show demyelination in microglia nodules in multiple sclerosis (MS), likely due to oxidized phospholipid phagocytosis and immune activation, suggesting that nodules could be involved in MS lesion formation.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 Netherlands Institute for Neuroscience, Neuroimmunology Research Group, Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263)
2 Amsterdam University Medical Center, Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)
3 Netherlands Institute for Neuroscience, Neuroimmunology Research Group, Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263); Erasmus Medical Center, MS Center ErasMS, Department of Neurology and Immunology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:0000 0004 0459 992X)
4 Netherlands Institute for Neuroscience, Neuroimmunology Research Group, Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263); University of Amsterdam, Swammerdam Institute for Life Sciences, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000 0000 8499 2262)
5 Netherlands Institute for Neuroscience, Neuroimmunology Research Group, Amsterdam, The Netherlands (GRID:grid.419918.c) (ISNI:0000 0001 2171 8263); Amsterdam University Medical Center, Department of Experimental Immunology, Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands (GRID:grid.509540.d) (ISNI:0000 0004 6880 3010)